Rhabdomyosarcoma in low- and middle-income countries: A report from the Asociacion de Hemato-oncología Pediatrica de Centro América (AHOPCA).
AHOPCA
low- and middle-income countries
outcome
protocol
rhabdomyosarcoma
treatment
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
25
02
2022
received:
02
12
2021
accepted:
02
03
2022
medline:
26
6
2023
pubmed:
17
3
2022
entrez:
16
3
2022
Statut:
ppublish
Résumé
This report describes the results of an observational study dedicated to rhabdomyosarcoma developed by the Asociación de Hemato-oncología Pediatrica de Centro América (AHOPCA) between 2001 and 2018. Overall, 337 previously untreated patients < 18 years old were included in the analysis; 58% had unresected disease, and 19% were metastatic at diagnosis. With a median follow-up of 6.6 years, five-year event-free and overall survival rates were 30% and 33%, respectively. Local progression/relapse was the main cause of treatment failure.
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29669Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Perez E, Kassira N, Cheung M, et al. Rhabdomyosarcoma in children: a SEER population based study. J Surg Res. 2011;170(2):e243-e251.
Skapek S, Ferrari A, Gupta A, et al. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019;5(1):1.
Hawkins D, Chi Y, Anderson J, et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group. Am J Clin Oncol. 2018;36(27):2770-2777.
Bisogno G, Jenney M, Bergeron C, et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol. 2018;19(8):1061-1071.
Bisogno G, De Salvo G, Bergeron C, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(11):1566-1575.
Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. Am J Clin Oncol. 2008;26(14):2384-2389.
Ferrari A, Gasparini P, Casanova M. A home run for rhabdomyosarcoma after 30 years: what now?. Tumori. 2020;106(1):5-11.
Rudzinski E, Kelsey A, Vokuhl C, et al. Pathology of childhood rhabdomyosarcoma: a consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. 2021;68(3):e28798.
Antillon F, Castellanos M, Valverde P, et al. Treating Pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatr Blood Cancer. 2008;51(6):760-764.
Al-Jumaily U, Ayyad O, Masarweh M, et al. Improved care of rhabdomyosarcoma in Jordan using less intensive therapy. Pediatr Blood Cancer. 2013;60(1):53-58.
Friedrich P, Ortiz R, Strait K, et al. Pediatric sarcoma in Central America: outcomes, challenges, and plans for improvement. J Cancer. 2013;119(4):871-879.
Bansal D, Das A, Trehan A, et al. Pediatric Rhabdomyosarcoma in India: a single-center experience. Indian Pediatr. 2017;54(9):735-738.
Van Der Schyff A, Fcpaed M, Stefan PDC. Clinical characteristics and outcome of rhabdomyosarcoma in South African children. Afr J Haematol Oncol. 2010;1:40-47.
Rodriguez-Galindo C, Friedrich P, Morrissey L, et al. Global challenges in pediatric oncology. Curr Opin Pediatr. 2013;25(1):3-15.
Barr R, Antillón F, Baez F, et al. Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology. Pediatr Blood Cancer. 2014;61(2):345-354.
Howard S, Ortiz R, Baez L, et al. Protocol-based treatment for children with cancer in low-income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-part II. Pediatr Blood Cancer. 2007;48(4):486-490.
Gupta S, Rivera-Luna R, Ribeiro R, et al. Pediatric oncology as the next global child health priority: the need for national childhood cancer strategies in low- and middle-income countries. PLoS Med. 2014;11(6):e1001656.
Crist W, Anderson J, Meza J, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. Am J Clin Oncol. 2001;19(12):3091-3102.
Raney R, Anderson J, Barr F, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. Pediatr Hematol Oncol J. 2001;23(4):215-220.
Maurer H, Beltangady M, Gehan E, et al. The intergroup rhabdomyosarcoma study-I: a final report. J Cancer. 1988;61(2):209-220.
Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
Papyan R, Tamamyan G, Danielyan S, et al. Identifying barriers to treatment of childhood rhabdomyosarcoma in resource-limited settings: a literature review. Pediatr Blood Cancer. 2019: e27708.
Adigun IA, Rahman GA, Buhari MO, Ogundipe KO, Omotayo JA. Pattern of rhabdomyosarcoma in Nigerian children. J Natl Med Assoc. 2008; 100: 906-909.
Ahmad Z, Din NU, Ahmad A, et al. Rhabdomyosarcoma: an epidemiological and histopathologic study of 277 cases from a major tertiary care center in Karachi, Pakistan. Asian Pacific J Cancer Prev. 2015;16:757-760.
Hessissen L, Kanouni L, Kili A, et al. Pediatric rhabdomyosarcoma in Morocco. Pediatr Blood Cancer. 2010;54:25-22.
Luna-Fineman S, Chantada G, Alejos A, et al. Delayed enucleation with neoadjuvant chemotherapy in advanced intraocular unilateral retinoblastoma: AHOPCA II, a prospective, multi-institutional protocol in Central America. Am J Clin Oncol. 2019;37(31):2875-2882.
Castellanos E, Barrantes J, Báez L, et al. A chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: AHOPCA LH 1999. Pediatr Blood Cancer. 2014;61(6):997-1002.
Peña-Hernandez A, Ortiz R, Garrido C, et al. Outcome of pediatric non-Hodgkin lymphoma in Central America: a report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA). Pediatr. Blood Cancer. 2019;66(5):e27621.
Arora RS, Eden T, Pizer B. The problem of treatment abandonment in children from developing countries with cancer. Pediatr Blood Cancer. 2007;49:941-946.
Friedrich P, Ortiz R, Fuentes S, et al. Barriers to effective treatment of pediatric solid tumors in middle-income countries: can we make sense of the spectrum of nonbiologic factors that influence outcomes?. Cancer. 2014;120(1):112-125.
Zubizarreta EH, Fidarova E, ealy B, Rosenblatt E. Need for radiotherapy in low and middle income countries - the silent crisis continues. Clin Oncol. 2014;27:107-114.
Abdel-Wahab M, Fidarova E, Polo A. Global access to radiotherapy in low- and middle-income countries. Clin Oncol (R Coll Radiol). 2017;29(2):99-104.